Article
Rheumatology
Edward Chia-Cheng Lai, Ya-Chun Huang, Tzu-Chi Liao, Meng-Yu Weng
Summary: This study found that primary Sjogren's syndrome, SLE, SSc, and SV are associated with an increased risk of premature coronary artery disease.
Article
Immunology
Mohamed Attauabi, Jakob Benedict Seidelin, Oluf Krautwald Felding, Mads Damsgaard Wewer, Laura Kirstine Vinther Arp, Melek Zahra Sarikaya, Alexander Egeberg, Nora Vladimirova, Flemming Bendtsen, Johan Burisch
Summary: The study found a lower occurrence but a more severe disease course of COVID-19 among patients with IMIDs, associated with the use of systemic steroids and suspension of other immunosuppressants. Therefore, it emphasizes the importance of weighing risks before suspending immunosuppressants during COVID-19.
JOURNAL OF AUTOIMMUNITY
(2021)
Article
Rheumatology
Eileen W. Stalman, Luuk Wieske, Koos P. J. van Dam, Laura Y. Kummer, Zoe L. E. van Kempen, Joep Killestein, Adriaan G. Volkers, Sander W. Tas, Laura Boekel, Gertjan J. Wolbink, Anneke J. Van der Kooi, Joost Raaphorst, Mark Lowenberg, R. Bart Takkenberg, Geert R. A. M. D'Haens, Phyllis Spuls, Marcel W. Bekkenk, Annelie H. Musters, Nicoline F. Post, Angela L. Bosma, Marc L. Hilhorst, Yosta Vegting, Frederique J. Bemelman, Alexandre E. Voskuyl, Bo Broens, Agner Parra Sanchez, Cecile A. C. M. van Els, Jelle De Wit, Abraham Rutgers, Karina de Leeuw, Barbara Horvath, Jan J. G. M. Verschuuren, Annabel M. Ruiter, Lotte van Ouwerkerk, Diane van der Woude, C. F. Allaart, Onno Y. K. Teng, Pieter van Paassen, Matthias H. Busch, Papay B. P. Jallah, Esther Brusse, Pieter A. van Doorn, Adaja Elisabeth Baars, Dirk Jan Hijnen, Corine R. G. Schreurs, W. Ludo Van der Pol, H. Stephan Goedee, Maurice Steenhuis, Sofie Keijzer, Jim B. D. Keijser, Arend Boogaard, Olvi Cristianawati, Anja ten Brinke, Niels J. M. Verstegen, Koos A. H. Zwinderman, Theo Rispens, S. Marieke van Ham, Taco W. Kuijpers, Filip Eftimov
Summary: This study compared the cumulative incidence and disease severity of reported SARS-CoV-2 omicron breakthrough infections between patients with immune-mediated inflammatory diseases (IMID) on immunosuppressants and controls. The results showed that the cumulative incidence of breakthrough infections was high but similar between the two groups, and the disease severity was mostly mild. Additional vaccinations and prior SARS-CoV-2 infections were associated with a decreased risk of breakthrough infections.
ANNALS OF THE RHEUMATIC DISEASES
(2022)
Review
Biochemistry & Molecular Biology
Lluis Rusinol, Luis Puig
Summary: The Jak/STAT pathways play a crucial role in cytokine signaling and have become a focus of research for immune-mediated inflammatory diseases. Dysfunction of Tyk2, a member of the Jak family, has been linked to protection from psoriasis and prevention of IMID without increasing the risk of serious infections. Deucravacitinib, an allosteric inhibitor that binds to the regulatory domain of Tyk2, has shown greater selectivity and a reduced risk of adverse events. In September 2022, deucravacitinib became the first Tyk2 inhibitor approved for the treatment of moderate-to-severe psoriasis. Tyk2 inhibitors hold promise for the future with the development of newer drugs and broader indications.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Review
Immunology
Zhanyan Gao, Yang Feng, Jinhua Xu, Jun Liang
Summary: This article reviews the research progress of T-cell exhaustion in several IMIDs and its potential application, revealing the important role of exhausted T-cells in autoimmunity and their association with favorable prognosis.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Cardiac & Cardiovascular Systems
A. S. Giordani, A. Candelora, M. Fiacca, C. Cheng, B. Barberio, A. Baritussio, R. Marcolongo, S. Iliceto, E. Carturan, M. De Gaspari, S. Rizzo, C. Basso, G. Tarantini, E. V. Savarino, A. L. P. Caforio
Summary: This study retrospectively analyzed data and conducted a literature review on myocarditis associated with inflammatory bowel diseases (IBD). It found that myocarditis in association with IBD is more common in young males and generally has a benign clinical course, but a subset of patients may develop giant cell myocarditis and require immunosuppression.
INTERNATIONAL JOURNAL OF CARDIOLOGY
(2023)
Article
Rheumatology
Giovanni Adami, Marco Pontalti, Giorgio Cattani, Maurizio Rossini, Ombretta Viapiana, Giovanni Orsolini, Camilla Benini, Eugenia Bertoldo, Elena Fracassi, Davide Gatti, Angelo Fassio
Summary: Long-term exposure to air pollution is associated with an increased risk of developing autoimmune diseases. Exposure to particulate matter concentrations above the threshold for human protection is associated with a higher risk of IMIDs.
Article
Immunology
Anne-Charlotte Heba, Simon Toupance, Djesia Arnone, Laurent Peyrin-Biroulet, Anthanase Benetos, Ndeye Coumba Ndiaye
Summary: Telomeres are repetitive DNA sequences located at the ends of linear chromosomes that play a crucial role in maintaining the integrity and stability of the genome. Research has shown a close connection between telomere length dynamics and immune-mediated inflammatory diseases, although the causality between these diseases and telomere attrition remains controversial.
JOURNAL OF AUTOIMMUNITY
(2021)
Review
Immunology
Serena Bert, Suchita Nadkarni, Mauro Perretti
Summary: Neutrophils, while being fundamental in combating infection and injury, are now recognized as key modulators of adaptive immune responses. This review explores the novel properties of neutrophils and redefines their pathophysiological functions, highlighting their role in mediating acute inflammatory responses and regulating adaptive immunity to maintain immune tolerance.
IMMUNOLOGICAL REVIEWS
(2023)
Article
Medicine, General & Internal
Rabia Khan, M. Ellen Kuenzig, Furong Tang, James H. B. Im, Jessica Widdifield, Jeffrey D. Mccurdy, Gilaad G. Kaplan, Eric I. Benchimol
Summary: This study investigated the risk of venous thromboembolisms (VTEs) in individuals with Immune-mediated inflammatory diseases (IMIDs) following COVID-19 infection. The study found that individuals with IMIDs did not have a higher risk of VTE compared to those without IMIDs.
Review
Immunology
Beatriz Garcillan, Miguel Salavert, Jose R. Regueiro, Sabela Diaz-Castroverde
Summary: Patients with immune-mediated inflammatory diseases (IMIDs) receiving biologic therapies may experience attenuated vaccine responses. Certain therapies impair the immunogenicity and antibody responses to vaccines, while others do not affect immune responses. SARS-CoV-2 vaccination appears to be safe and well tolerated in IMID patients, but the efficacy may be reduced compared to healthy individuals.
Review
Rheumatology
Shirish Dubey, Nilay Joshi, Olivia Stevenson, Caroline Gordon, John A. Reynolds
Summary: This review focuses on chilblains secondary to immune-mediated inflammatory disorders, primarily discussing the epidemiology, pathogenesis, and treatment of CHLE.
Review
Immunology
Ainsley Ryan Yan Bin Lee, Shi Yin Wong, Sen Hee Tay
Summary: This study conducted a systematic review and meta-analysis on the efficacy of COVID-19 booster vaccines. The results showed that booster doses are effective in inducing seroconversion in non-responders and are not associated with major adverse events.
Article
Medicine, General & Internal
Francesco Salvatore Iaquinta, Rosa Daniela Grembiale, Daniele Mauro, Ilenia Pantano, Saverio Naty, Cristina Cosco, Daniela Iacono, Emanuela Gaggiano, Annarita Ruggiero, Francesco Ciccia, Patrizia Doldo, Rocco Spagnuolo
Summary: This study assessed the prevalence of fatigue and its associated factors in patients with immune-mediated inflammatory diseases (IMIDs). The results showed that anxiety and depression were the main factors associated with fatigue, suggesting a psychological component of the symptom. This highlights the need for a comprehensive management approach.
JOURNAL OF CLINICAL MEDICINE
(2022)
Review
Nutrition & Dietetics
Yan Jiang, Karolin Jarr, Cosima Layton, Christopher D. Gardner, Judith E. Ashouri, Maria T. Abreu, Sidhartha R. Sinha
Summary: Despite being an important issue for patients, the impact of diet on adult inflammatory bowel disease (IBD) is not well explored, with limited guidance. Current evidence on various diets used in the treatment of IBD is summarized, with potential applications of dietary data from related immune-mediated inflammatory diseases (IMIDs) to inform providers. Multiple diets, including Mediterranean, vegetarian/vegan, and reduced-calorie/fasting diets, have shown positive results in other inflammatory diseases, suggesting potential applicability to IBD, but further well-designed clinical trials are needed for guidance.
Article
Gastroenterology & Hepatology
Joana Torres, Maria Chaparro, Mette Julsgaard, Konstantinos Katsanos, Zuzana Zelinkova, Manasi Agrawal, Sandro Ardizzone, Marjo Campmans-Kuijpers, Gabriele Dragoni, Marc Ferrante, Gionata Fiorino, Emma Flanagan, Catarina Frias Gomes, Ailsa Hart, Charlotte Rose Hedin, Pascal Juillerat, Annemarie Mulders, Par Myrelid, Aoibhlinn O'Toole, Pauline Riviere, Michael Scharl, Christian Philipp Selinger, Elena Sonnenberg, Murat Toruner, Jantien Wieringa, C. Janneke Van der Woude
JOURNAL OF CROHNS & COLITIS
(2023)
Letter
Gastroenterology & Hepatology
Manasi Agrawal, Heidi S. Christensen, Jean-frederic Colombel, Tine Jess, Kristine H. Allin
Article
Gastroenterology & Hepatology
Adam S. Faye, Kristine Hojgaard Allin, Aske T. Iversen, Manasi Agrawal, Jeremiah Faith, Jean-Frederic Colombel, Tine Jess
Summary: This study used Danish nationwide registries to investigate the association between antibiotic exposure and the risk of inflammatory bowel disease (IBD). The results showed that antibiotic exposure was associated with an increased risk of IBD, especially in individuals aged 40 years and older. The risk was highest within 1-2 years after antibiotic exposure and with the use of antibiotics targeting gastrointestinal pathogens.
Article
Gastroenterology & Hepatology
Hannah Gordon, Livia Biancone, Gionata Fiorino, Konstantinos H. Katsanos, Uri Kopylov, Eman Al Sulais, Jordan E. Axelrad, Karthiha Balendran, Johan Burisch, Lissy de Ridder, Lauranne Derikx, Pierre Ellul, Thomas Greuter, Marietta Iacucci, Caroline Di Jiang, Christina Kapizioni, Konstantinos Karmiris, Julien Kirchgesner, David Laharie, Triana Lobaton, Tamas Molnar, Nurulamin M. Noor, Rohit Rao, Simone Saibeni, Michael Scharl, Stephan R. Vavricka, Tim Raine
JOURNAL OF CROHNS & COLITIS
(2023)
Review
Gastroenterology & Hepatology
Sigrun Grimsdottir, Mohamed Attauabi, Emilie Kristine Dahl, Johan Burisch, Jakob Benedict Seidelin
Summary: A systematic review found that a high proportion of patients with inflammatory bowel disease (IBD) experience flares following cancer treatment, with an increased risk of gastrointestinal toxicity in IBD patients receiving immune checkpoint inhibitor treatment. However, current studies suggest that IBD flares induced by cancer therapy can be managed and should not prevent appropriate cancer treatments.
JOURNAL OF CROHNS & COLITIS
(2023)
Editorial Material
Gastroenterology & Hepatology
Manasi Agrawal, Joana Torres
UNITED EUROPEAN GASTROENTEROLOGY JOURNAL
(2023)
Editorial Material
Gastroenterology & Hepatology
Johan Burisch
UNITED EUROPEAN GASTROENTEROLOGY JOURNAL
(2023)
Article
Gastroenterology & Hepatology
Manasi Agrawal, Anthony C. Ebert, Gry Poulsen, Ryan C. Ungaro, Adam S. Faye, Tine Jess, Jean-Frederic Colombel, Kristine H. Allin
Summary: This study compared the long-term outcomes of primary ileocecal resection (ICR) and anti-tumor necrosis factor (TNF) therapy in patients with ileocecal Crohn's disease (CD). The results showed that the risk of the composite outcome was 33% lower with ICR compared to anti-TNF therapy. ICR was also associated with a reduced risk of systemic corticosteroid exposure and CD-related surgery.
Review
Gastroenterology & Hepatology
Johan Burisch, Ekaterina Safroneeva, Raphael Laoun, Christopher Ma
Summary: Although UC and CD share common pathways and treatments, CD patients are more likely to undergo surgery than UC patients. Early treatment in CD can modify the disease's natural history, but there is limited evidence supporting the utility of early escalation to advanced therapies in UC. More data is needed to determine the meaningfulness of different outcomes in UC and to analyze different populations of UC patients.
JOURNAL OF CROHNS & COLITIS
(2023)
Article
Gastroenterology & Hepatology
Hannah Gordon, Johan Burisch, Pierre Ellul, Konstantinos Karmiris, Konstantinos Katsanos, Mariangela Allocca, Giorgos Bamias, Manuel Barreiro-de Acosta, Tasanee Braithwaite, Thomas Greuter, Catherine Harwood, Pascal Juillerat, Triana Lobaton, Ulf Mueller-Ladner, Nurulamin Noor, Gianluca Pellino, Edoardo Savarino, Christoph Schramm, Alessandra Soriano, Juergen Michael Stein, Mathieu Uzzan, Patrick F. van Rheenen, Stephan R. Vavricka, Maurizio Vecchi, Stephane Zuily, Torsten Kucharzik
JOURNAL OF CROHNS & COLITIS
(2023)
Article
Gastroenterology & Hepatology
Manasi Agrawal, Kristine H. Allin, Saurabh Mehandru, Jeremiah Faith, Tine Jess, Jean-Frederic Colombel
Summary: The appendix is believed to play a role in the development of ulcerative colitis, but the exact nature of this association is still unclear. This Perspective discusses the immunological function and microbiome of the appendix and how they may relate to its potential involvement in ulcerative colitis. Experimental models have shown that removal of the inflamed appendix prevents colitis, and observational studies in humans have found that appendectomy is associated with protection against ulcerative colitis. Further research is needed to determine the clinical relevance of the connection between the appendix and ulcerative colitis.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY
(2023)
Article
Gastroenterology & Hepatology
Kristoffer Jarlov Jensen, Camilla Bjorn Jensen, Christina Wennerstroem, Johan Burisch, Janne Petersen
Summary: This study aimed to characterize the drug utilization and switch patterns of biological treatment for ulcerative colitis (UC) and Crohn's disease (CD). The majority of UC and CD patients initiating biologic therapy chose infliximab as their first-line treatment. Adalimumab had a higher risk of treatment discontinuation compared to infliximab, while vedolizumab had a lower risk of discontinuation for UC patients.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY
(2023)
Article
Dentistry, Oral Surgery & Medicine
Kristina Bertl, Georgios Tsakos, Nikolaos Pandis, Anna Bogren, Johan Burisch, Andreas Stavropoulos
Summary: This study is the first to find that oral health problems are associated with the disease-specific quality of life (QoL) of inflammatory bowel disease (IBD) patients, and vice versa. This emphasizes the potential advantages of including dental professionals in the multi-disciplinary treatment teams of IBD patients.
JOURNAL OF CLINICAL PERIODONTOLOGY
(2023)
Article
Dentistry, Oral Surgery & Medicine
Kristina Bertl, Johan Burisch, Nikolaos Pandis, Bjorn Klinge, Andreas Stavropoulos
Summary: Patients with inflammatory bowel disease (IBD) have a higher frequency and impact of oral lesions and higher costs for professional dental care compared to matched controls.
JOURNAL OF PERIODONTOLOGY
(2023)
Article
Gastroenterology & Hepatology
Anne-Sofie H. Jensen, Marie Winther-Sorensen, Johan Burisch, Annika Bergquist, Henriette Ytting, Lise L. Gluud, Nicolai J. Wewer Albrechtsen
Summary: Patients with autoimmune liver diseases have a significantly increased risk of diabetes. Increased awareness of diabetes risk in patients with autoimmune liver diseases is warranted.
LIVER INTERNATIONAL
(2023)
Article
Immunology
Shane Kelly, Katherine J. L. Jackson, Timothy J. Peters, Dan Suan, Christopher C. Goodnow
Summary: This study successfully identified and characterized PR3-specific B cells from the peripheral blood of patients with PR3 autoantibodies. These cells exhibited specific immunological features, suggesting that PR3 self-reactivity may occur early in B-cell development.
JOURNAL OF AUTOIMMUNITY
(2024)
Article
Immunology
Ana Merino-Vico, Jan Piet van Hamburg, Paul Tuijnenburg, Giulia Frazzei, Aram Al-Soudi, Carlo G. Bonasia, Boy Helder, Abraham Rutgers, Wayel H. Abdulahad, Coen A. Stegeman, Jan-Stephan Sanders, Laura Bergamaschi, Paul A. Lyons, Theo Bijma, Laura van Keep, Kirsten Wesenhagen, Aldo Jongejan, Henric Olsson, Niek de Vries, Taco W. Kuijpers, Peter Heeringa, Sander W. Tas
Summary: B lineage cells play a critical role in ANCA-associated vasculitis (AAV), and the transcription factor NF-kappa B may be a potential therapeutic target for AAV and other autoimmune diseases with prominent B cell involvement.
JOURNAL OF AUTOIMMUNITY
(2024)
Article
Immunology
Christopher Nelke, Thomas Muentefering, Derya Cengiz, Lukas Theissen, Vera Dobelmann, Christina B. Schroeter, Helena Block, Corinna Preu, Alexander P. E. Michels, Stefanie Lichtenberg, Marc Pawlitzki, Steffen Pfeuffer, Niklas Huntemann, Alexander Zarbock, Thorben Briese, Christoph Kittl, Carsten Dittmayer, Thomas Budde, Ingrid E. Lundberg, Werner Stenzel, Sven G. Meuth, Tobias Ruck
Summary: K2P2.1 plays a regulatory role in the autoimmune response of idiopathic inflammatory myopathies (IIMs), by regulating inflammatory cell response, adhesion, and transmigration in both endothelial and skeletal muscle cells. Inhibiting K2P2.1 enhances the inflammatory response, while activating K2P2.1 improves the disease course.
JOURNAL OF AUTOIMMUNITY
(2024)
Article
Immunology
Xuan Zhang, Jun Xia, Ying Jiang, David S. Pisetsky, Josef S. Smolen, Rong Mu, Shengming Dai, Michael E. Weinblatt, Tore K. Kvien, Juan Li, Thomas Doerner, Yu Zhang, Liwei Lu, Chengde Yang, Pingting Yang, Yuan Zhang, Chenchen Xu, Zhan Zhao, Peter E. Lipsky
Summary: The study suggests that TwHF may be as effective as MTX in treating active RA, and combination therapy may be more effective than monotherapy.
JOURNAL OF AUTOIMMUNITY
(2024)
Article
Immunology
Maya F. Amjadi, Maxwell H. Parker, Ryan R. Adyniec, Zihao Zheng, Alex M. Robbins, S. Janna Bashar, Michael F. Denny, Sara S. Mccoy, Irene M. Ong, Miriam A. Shelef
Summary: Rheumatoid factors (RFs) are polyreactive antibodies that can bind disease-specific epitopes. Recent studies have found that RFs in COVID-19 can bind novel IgG epitopes, which provides new insights into the mechanism of RFs.
JOURNAL OF AUTOIMMUNITY
(2024)
Article
Immunology
Johanne Liberatore, Yann Nguyen, Jerome Hadjadj, Pascal Cohen, Luc Mouthon, Xavier Puechal, Loic Guillevin, Benjamin Terrier
Summary: B-cell depletion induced by rituximab (RTX) in ANCA-associated vasculitis (AAV) can lead to decreased gammaglobulin levels, which is associated with an increased risk of relapse and severe infections. Older age, low gammaglobulin levels, and receiving pulses of methylprednisolone at induction therapy are risk factors for gammaglobulin decline.
JOURNAL OF AUTOIMMUNITY
(2024)